RU2016134130A3 - - Google Patents

Download PDF

Info

Publication number
RU2016134130A3
RU2016134130A3 RU2016134130A RU2016134130A RU2016134130A3 RU 2016134130 A3 RU2016134130 A3 RU 2016134130A3 RU 2016134130 A RU2016134130 A RU 2016134130A RU 2016134130 A RU2016134130 A RU 2016134130A RU 2016134130 A3 RU2016134130 A3 RU 2016134130A3
Authority
RU
Russia
Application number
RU2016134130A
Other languages
Russian (ru)
Other versions
RU2016134130A (ru
RU2689788C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016134130A publication Critical patent/RU2016134130A/ru
Publication of RU2016134130A3 publication Critical patent/RU2016134130A3/ru
Application granted granted Critical
Publication of RU2689788C2 publication Critical patent/RU2689788C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2016134130A 2014-01-22 2015-01-21 ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ RU2689788C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14152202 2014-01-22
EP14152202.9 2014-01-22
PCT/EP2015/051177 WO2015110491A2 (en) 2014-01-22 2015-01-21 Pyrazolo[1,5-a]pyrimidin-7-amine derivatives useful in therapy

Publications (3)

Publication Number Publication Date
RU2016134130A RU2016134130A (ru) 2018-02-26
RU2016134130A3 true RU2016134130A3 (enExample) 2018-08-30
RU2689788C2 RU2689788C2 (ru) 2019-05-29

Family

ID=49989585

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016134130A RU2689788C2 (ru) 2014-01-22 2015-01-21 ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ

Country Status (11)

Country Link
US (1) US9963455B2 (enExample)
EP (1) EP3096762B1 (enExample)
JP (1) JP6509238B2 (enExample)
CN (1) CN106061975B (enExample)
AU (1) AU2015208205B2 (enExample)
BR (1) BR112016016798B1 (enExample)
CA (1) CA2935658C (enExample)
ES (1) ES2954126T3 (enExample)
RU (1) RU2689788C2 (enExample)
WO (1) WO2015110491A2 (enExample)
ZA (1) ZA201605666B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3057408A1 (en) * 2017-04-05 2018-10-11 Curovir Ab Heteroaromatic compounds useful in therapy
BR112020014431A2 (pt) * 2018-01-17 2020-12-01 Glaxosmithkline Intellectual Property Development Limited inibidores de pl4kiiibeta
CN108727386A (zh) * 2018-07-16 2018-11-02 广州医科大学 一种吡唑并嘧啶类化合物及其制备方法和用途
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
WO2020074159A1 (en) * 2018-10-10 2020-04-16 Curovir Ab 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
EP4028131B1 (en) 2019-08-20 2023-11-22 Curovir Ab Heteroaromatic compounds useful in therapy
WO2024184442A1 (en) 2023-03-09 2024-09-12 Curovir Ab Compound and formulation for systemic therapy by oral transmucosal administration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2585462B2 (ja) * 1989-10-25 1997-02-26 株式会社大塚製薬工場 ピラゾロ[1,5―a]ピリミジン誘導体
AU651986B2 (en) * 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
AU7738100A (en) * 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
ATE365740T1 (de) * 2002-05-10 2007-07-15 Smithkline Beecham Corp Substituierte pyrazolopyrimidine
MXPA05002572A (es) * 2002-09-04 2005-09-08 Schering Corp Compuestos pirazolo[1,5-a]pirimidinas como inhibidores de cinasa depentes de ciclina.
US7601724B2 (en) * 2002-09-04 2009-10-13 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
WO2010086040A1 (en) * 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
KR101478889B1 (ko) * 2010-02-26 2015-01-02 미쓰비시 타나베 파마 코퍼레이션 피라졸로피리미딘 화합물 및 pde10 억제제로서의 그의 용도
US8633198B1 (en) * 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase

Also Published As

Publication number Publication date
CA2935658C (en) 2023-02-21
NZ722290A (en) 2021-08-27
WO2015110491A3 (en) 2015-09-17
JP6509238B2 (ja) 2019-05-08
ZA201605666B (en) 2021-01-27
EP3096762B1 (en) 2023-06-28
EP3096762C0 (en) 2023-06-28
BR112016016798B1 (pt) 2022-06-28
CA2935658A1 (en) 2015-07-30
US9963455B2 (en) 2018-05-08
WO2015110491A2 (en) 2015-07-30
AU2015208205A1 (en) 2016-08-18
RU2016134130A (ru) 2018-02-26
CN106061975B (zh) 2019-09-24
EP3096762A2 (en) 2016-11-30
JP2017503830A (ja) 2017-02-02
US20160318937A1 (en) 2016-11-03
RU2689788C2 (ru) 2019-05-29
BR112016016798A2 (enExample) 2017-08-08
CN106061975A (zh) 2016-10-26
AU2015208205B2 (en) 2019-12-05
ES2954126T3 (es) 2023-11-20

Similar Documents

Publication Publication Date Title
BR112016017520A2 (enExample)
BR112016016951A2 (enExample)
BR112016016756A2 (enExample)
BR112016016478A2 (enExample)
BR112016016978A2 (enExample)
BR112016018948A2 (enExample)
BR112016018327A2 (enExample)
BR112016015605A2 (enExample)
BR112016018868A2 (enExample)
BR112016018384A2 (enExample)
BR112016018278A2 (enExample)
BR112016018582A2 (enExample)
BR112016018556A2 (enExample)
BR112016015385A2 (enExample)
BR112016018865A2 (enExample)
BR112016017262A2 (enExample)
BR112016008129A2 (enExample)
BR112016016933A2 (enExample)
BR112016016364A2 (enExample)
BR112016014460A2 (enExample)
BR112016017713A2 (enExample)
BR112016016298A2 (enExample)
BR112016018944A2 (enExample)
BR112016015645A2 (enExample)
BR112016000228A2 (enExample)